NASDAQ · Biotechnology

MNOV (MNOV) Stock

$1.31 -0.76% NASDAQ: MNOV Healthcare

Valuation

MetricValue
Price$1.31
Market Cap$64.48M
P/E Ratio-5.75
P/B Ratio1.62
P/S Ratio115.08
EPS (TTM)$-0.24
52-Week High$1.96
52-Week Low$1.17
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-28.57%
ROA-26.09%
ROCE-30.95%
Gross Margin15.20%
Operating Margin-21.65%
Net Margin-19.64%
Debt/Equity0.00
Current Ratio7.75

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$0$1.0M$0$0
Operating Profit$-10.0M$-15.0M$-10.0M$-13.0M$-13.0M
Net Profit$-10.0M$-14.0M$-9.0M$-11.0M$-12.0M
EPS$-0.21$-0.29$-0.17$-0.23$-0.24
Op Margin-253.0%—-990.0%—-3242.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$87.0M$74.0M$66.0M$56.0M$46.0M
Total Liabilities$4.0M$4.0M$4.0M$3.0M$4.0M
Cash$71.0M$19.0M$51.0M$40.0M$31.0M
Borrowings$1.0M$1.0M$0$0$0

Latest News

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients GlobeNewswire · Jul 15, 2026 MediciNova CEO Provides Shareholder Update GlobeNewswire · Jun 30, 2026 Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight GlobeNewswire · Jun 8, 2026 MediciNova Granted US Patent Notice of Allowance for Ibudilast Combination to Treat Brain Cancer MT Newswires · Jun 8, 2026 MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment GlobeNewswire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-9.0M$-13.0M$-7.0M$-11.0M$-10.0M
Investing Cash Flow$0$-40.0M$40.0M$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$11.0M$-53.0M$32.0M$-11.0M$-10.0M
Free Cash Flow$-9.0M$-13.0M$-7.0M$-11.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-13.85%
Quick Ratio9.09
Interest Coverage—
Return 1Y10.60%
Return 3Y-46.86%
Return 5Y-64.11%

Ownership

Insiders Held2.88%
Institutions Held11.04%
Institutions Float Held11.36%
Institutional HolderSharesReport Date
Essex Woodlands Management Inc.1,105,9412026-03-31
Blackrock Inc.705,9542026-03-31
Citigroup Inc.635,7152026-03-31
Vanguard Capital Management LLC611,0392026-03-31
Geode Capital Management, LLC543,8432026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRV $1.73 +2.37% -0.95 $74.05M 0.00%
BMEA $1.22 +0.00% -1.20 $88.21M 0.00%
CBUS $1.93 +0.00% -0.50 $87.79M 0.00%
FBIO $2.67 -3.61% 0.91 $88.69M 0.00%
IMUXImmunic, Inc. $13.81 +3.14% -2.24 $188.11M 0.00%

About MNOV

MNOV is led by CEO Yuichi Iwaki, employs 13 people, headquartered in US, publicly traded since 2006.

MNOV stock trades at $1.31 with a market capitalization of $64.48M. The stock is valued at a price-to-earnings (P/E) ratio of -5.75, price-to-book of 1.62, price-to-sales of 115.08. Over the past 52 weeks the stock has ranged between $1.17 and $1.96, and currently trades 33.2% below its 52-week high.

On profitability, MNOV generates a return on equity (ROE) of -28.57%, return on capital employed of -30.95%, an operating margin of -21.65%, a net profit margin of -19.64%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides